Chimerix
aligned criteria for phase efficacy analysis to isolate single agent activity eligibility | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
8 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
aligned criteria for phase efficacy analysis to isolate single agent activity eligibility | Chimerix
Investor Presentation
March 2023
aligned criteria for phase efficacy analysis to isolate single agent activity eligibility | Chimerix
Investor Conference
November 2021
integrated efficacy analysis objective and eligibility criteria | Chimerix
Related slides by other companies
GH Research
Investor Presentation
May 2023
phase single dose efficacy | GH Research
GH Research
Investor Presentation
March 2023
phase single dose efficacy | GH Research
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights